Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T de Witte

Showing results (161-170 of 215) with videos related to

Pageof 22
Sort By:
Annals of Hematology|April 1, 2014
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)R Willemze, S Suciu, P Muus, et al.
Bone Marrow Transplantation|January 1, 1996
Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT)F Frassoni, M Labopin, E Gluckman, et al.
British Journal of Haematology|September 6, 2000
No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)J Y Cahn, M Labopin, J Sierra, et al.
Leukemia|July 6, 2007
A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)H K Al-Ali, R Brand, A van Biezen, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 28, 2010
Solid organ transplantation after allogeneic hematopoietic stem cell transplantation: a retrospective, multicenter study of the EBMTC Koenecke, B Hertenstein, J Schetelig, et al.
Leukemia|November 26, 2011
Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden ConsortiumW Wiktor-Jedrzejczak, C Dearden, L de Wreede, et al.
Bone Marrow Transplantation|November 9, 2004
Stem cell transplantation from identical twins in patients with myelodysplastic syndromesN Kröger, R Brand, A van Biezen, et al.
Bone Marrow Transplantation|June 13, 2000
Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantationB Simonsson, T Tötterman, P Hokland, et al.
Blood|June 14, 2000
A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host diseaseY V van Oosterhout, L van Emst, A V Schattenberg, et al.
Bone Marrow Transplantation|April 15, 2003
An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantationA J Peniket, M C Ruiz de Elvira, G Taghipour, et al.
Pageof 22

Showing results (161-170 of 215) with videos related to

Sort By:
Pageof 22
Annals of Hematology|April 1, 2014
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)R Willemze, S Suciu, P Muus, et al.
Bone Marrow Transplantation|January 1, 1996
Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT)F Frassoni, M Labopin, E Gluckman, et al.
British Journal of Haematology|September 6, 2000
No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)J Y Cahn, M Labopin, J Sierra, et al.
Leukemia|July 6, 2007
A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)H K Al-Ali, R Brand, A van Biezen, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 28, 2010
Solid organ transplantation after allogeneic hematopoietic stem cell transplantation: a retrospective, multicenter study of the EBMTC Koenecke, B Hertenstein, J Schetelig, et al.
Leukemia|November 26, 2011
Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden ConsortiumW Wiktor-Jedrzejczak, C Dearden, L de Wreede, et al.
Bone Marrow Transplantation|November 9, 2004
Stem cell transplantation from identical twins in patients with myelodysplastic syndromesN Kröger, R Brand, A van Biezen, et al.
Bone Marrow Transplantation|June 13, 2000
Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantationB Simonsson, T Tötterman, P Hokland, et al.
Blood|June 14, 2000
A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host diseaseY V van Oosterhout, L van Emst, A V Schattenberg, et al.
Bone Marrow Transplantation|April 15, 2003
An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantationA J Peniket, M C Ruiz de Elvira, G Taghipour, et al.
Pageof 22